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Abstract
Painful diabetic neuropathy is a common complication of diabetes mellitus which is poorly
controlled by conventional analgesics. This study investigates if treatment with an heme
oxygenase 1 (HO-1) inducer, cobalt protoporphyrin IX (CoPP), could modulate the allodynia
and hyperalgesia induced by diabetes and enhanced the antinociceptive effects of mor-
phine. In a diabetic mice model induced by the injection of streptozotocin (STZ), we evalu-
ated the antiallodynic and antihyperalgesic effects produced by the intraperitoneal
administration of 5 and 10 mg/kg of CoPP at several days after its administration. The anti-
nociceptive actions produced by the systemic administration of morphine alone or com-
bined with CoPP were also evaluated. In addition, the effects of CoPP treatment on the
expression of HO-1, the microglial activation marker (CD11b/c), the inducible nitric oxide
synthase (NOS2) and μ-opioid receptors (MOR), were also assessed. Our results showed
that the administration of 10 mg/kg of CoPP during 5 consecutive days completely blocked
the mechanical and thermal hypersensitivity induced by diabetes. These effects are accom-
panied by the increased spinal cord, dorsal root ganglia and sciatic nerve protein levels of
HO-1. In addition, the STZ-induced activation of microglia and overexpression of NOS2 in
the spinal cord were inhibited by CoPP treatment. Furthermore, the antinociceptive effects
of morphine were enhanced by CoPP treatment and reversed by the administration of an
HO-1 inhibitor, tin protoporphyrin IX (SnPP). The spinal cord expression of MOR was also
increased by CoPP treatment in diabetic mice. In conclusion, our data provide the first evi-
dence that the induction of HO-1 attenuated STZ-induced painful diabetic neuropathy and
enhanced the antinociceptive effects of morphine via inhibition of microglia activation and
NOS2 overexpression as well as by increasing the spinal cord levels of MOR. This study
proposes the administration of CoPP alone or combined with morphine as an interesting
therapeutic approach for the treatment of painful diabetic neuropathy.
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Introduction
Neuropathic pain is one of the most common complications of diabetes, occurring in nearly
50% of patients [1] and remains an important clinical problem due to resistance to classical
opioid analgesic drugs, such as morphine [2–6]. This loss in antinociceptive efficacy was
described in diabetic animals following the systemic [2, 7], spinal [5, 8] and supraspinal [8]
administration of μ-opioid receptor (MOR) agonists. As a consequence, high doses of mor-
phine are required to inhibit neuropathic pain resulting in the induction of several side effects
such sedation, respiratory depression, constipation and tolerance, among others [9].
Different mechanisms involving neuronal and non-neuronal factors were postulated to be
responsible for the reduction in MOR agonists antinociceptive efficacy during painful diabetic
neuropathy [4, 5, 10, 11]. That is, while several studies have demonstrated that this effect was
associated with a loss of MOR and/or an impaired G-protein coupling to MOR [5, 10]. Other
studies suggested that the activation of non-neuronal cells in the spinal cord, such as microglia,
participates in the reduced antinociceptive effects produced by morphine under diabetic pain
conditions. Indeed, the administration of minocycline, an specific inhibitor of microglia,
potentiated the analgesic activity of morphine in STZ-induced diabetic neuropathy in mice
[11]. Nevertheless, the search of new strategies to treat painful diabetic neuropathy and/or
improve the analgesic effects of morphine during diabetic neuropathy is required.
Carbon monoxide is a gaseous neurotransmitter synthesized by the inducible (HO-1) and
constitutive heme oxygenase enzymes. Several studies have shown that HO-1 over-expression
or induction is associated with potent anti-inflammatory and antinociceptive effects [12–15].
Indeed, the administration of HO-1 inducer compounds, such as cobalt protoporphyrin IX
(CoPP) inhibits acute and chronic pain. That is, the systemic administration of CoPP inhibits
acute thermal nociception [16], inflammatory pain induced by the peripheral injection of for-
malin [17, 18] and the acetic acid-induced visceral pain [18]. In chronic pain, the administra-
tion of CoPP also inhibited the mechanical and thermal hypersensitivity induced by knee and
paw inflammation [18, 19] among to those induced by the partial or total sciatic nerve injury
as well as by the vincristine-induced neuropathic pain [14, 18, 20]. However the possible anti-
nociceptive effects produced by CoPP treatment during painful diabetic neuropathy has not
been evaluated.
We have also recently demonstrated that the administration of CoPP significantly enhanced
the antiallodynic and antihyperalgesic effects produced by the local administration of mor-
phine in acute thermal [16] and chronic inflammatory [18, 19] or nerve injury-induced neuro-
pathic pain [18, 21]. Moreover, its antinociceptive effects were significantly decreased by the
administration of the HO-1 inhibitor tin protoporphyrin IX (SnPP), indicating that HO-1 par-
ticipates in the analgesic effects produced by morphine during acute and chronic inflammatory
or nerve-injury induced neuropathic pain. Nevertheless, the role played by CoPP treatment on
the antinociceptive effects of morphine during painful diabetic neuropathy and the possible
mechanism involved in this action have not been evaluated.
In the other hand, it is well accepted that the spinal cord microglial cells are a key player in
the etiology of diabetic neuropathic pain [22, 23]. That is hyperglycemia activated microglia
and intracellular signaling molecules that are implicated in microglial functions including
intracellular kinases (e.g., mitogen-activated protein kinases, MAPKs), and the release a variety
of inflammatory mediators (such as proinflammatory cytokines, chemokines, nitric oxide,
reactive oxygen species, etc.), which amplify the nociceptive signals in the spinal cord [24–27].
Oxidative stress and changes in nitric oxide formation played major roles in the onset of dia-
betic complications. Nitric oxide produced by the inducible nitric oxide synthase (NOS2) has
been implicated in diabetic neuropathy as demonstrated by the reduced allodynia observed in
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diabetic NOS2 deficient mice [28]. In addition, previous studies have demonstrated that the
exogenous induction of HO-1 alleviated neuropathic pain induced by sciatic nerve injury by
reducing spinal cord microglia activation and nitric oxide synthesis [14]. However, whether
HO-1 induction might avoid spinal microglial activation and reduces the liberation of inflam-
matory mediators, such us nitric oxide synthetized by NOS2 in diabetic neuropathy, remained
to be investigated.
In the present study, using a mouse model of painful diabetic neuropathy induced by the
intraperitoneal administration of streptozotocin (STZ), we evaluated: 1) the antiallodynic and
antihyperalgesic effects produced by the intraperitoneal administration of CoPP; 2) the antino-
ciceptive effects of the subcutaneous administration of morphine (a specific MOR agonist)
alone and combined with CoPP; 2) the reversion of the antinociceptive effects of morphine
with the HO-1 inhibitor, SnPP and 3) the effects of CoPP on the protein levels of HO-1 in the
spinal cord, dorsal root ganglia and sciatic nerve as well as of those of CD11b/c (as a marker of
microglial activation), NOS2 and MOR in the spinal cord from STZ-injected mice.
Materials and Methods
Animals
In vivo experiments were performed in male C57BL/6J mice acquired from Harlan Laborato-
ries (Barcelona, Spain). All mice between 8 to 10 weeks old and weighing 21 to 25 g were
housed under 12-h/12-h light/ dark conditions in a room with controlled temperature (22°C)
and humidity (66%). Animals had free access to food and water and were used after a mini-
mum of 6 days acclimatization to the housing conditions. All experiments were conducted
between 9:00 AM and 5:00 PM. All experimental procedures within this study were carried out
in accordance with the recommendations in the Guide for the Care and Use of Laboratory Ani-
mals of the National Institutes of Health. The protocol was approved by the local Ethical Com-
mittee of our Institution (Comissió d’Etica en l’Experimentació Animal i Humana de la
Universitat Autònoma de Barcelona). This study was carried out in strict accordance with Uni-
versitat Autònoma de Barcelona (Permit Number: 6266). All efforts were made to minimize
animal suffering and to reduce the number of animals used.
Induction of Painful Diabetic Neuropathy
Diabetes was induced by the intraperitoneal administration of five consecutive daily injections
of 55 mg/kg of streptozotocin (STZ; Sigma-Aldrich, St. Louis, MO) freshly prepared in citrate
buffer (0.1M, pH 4.5) [29]. Control animals received an equal volume of citrate buffer alone
(CTRL). Animals were fasted prior to the first administration of STZ and were allowed to feed
again after injection. At 21 days after the first injection of STZ, the tail vein blood glucose levels
were measured to confirm hyperglycemia by using a glucometer (OneTouch1 UltraMini1). In
accordance to the recommendations established by [30], in this study we avoided the use of
tests that animals restraint was required during measurements and employed multiple behav-
ioral tests to identify the development of painful diabetic neuropathy in mice. That is, the
development of mechanical allodynia, thermal hyperalgesia and thermal allodynia was evalu-
ated by using the von Frey filaments, plantar and cold plate tests, respectively.
Nociceptive Behavioral Tests
Mechanical allodynia was quantified by measuring the hind paw withdrawal response to von
Frey filament stimulation. In brief, animals were placed in methacrylate cylinders (20 cm high,
9 cm diameter; Servei Estació, Barcelona, Spain) with a wire grid bottom through which the
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von Frey filaments (North Coast Medical, Inc., San Jose, CA) with a bending force in the range
of 0.008–3.5 g were applied by using a modified version of the up–down paradigm, as previ-
ously reported by Chaplan et al. (1994) [31]. The filament of 3.0 g was used as a cut-off. Then,
the strength of the next filament was decreased or increased according to the response. The
threshold of response was calculated from the sequence of filament strength used during the
up–down procedure by using an Excel program (Microsoft Iberia SRL, Barcelona, Spain) that
includes curve fitting of the data. Clear paw withdrawal, shaking, or licking of the paw was
considered as a nociceptive-like response. Both ipsilateral and contralateral hind paws were
tested. Animals were allowed to habituate for 1 h before testing in order to allow an appropriate
behavioral immobility.
Thermal hyperalgesia was assessed as previously reported by Hargreaves et al. (1988) [32].
Paw withdrawal latency in response to radiant heat was measured using the plantar test appa-
ratus (Ugo Basile, Varese, Italy). Briefly, mice were placed in methacrylate cylinders (20 cm
high x 9 cm diameter) positioned on a glass surface. The heat source was positioned under the
plantar surface of the hind paw and activated with a light beam intensity. A cut-off time of 12 s
was used to prevent tissue damage in absence of response. The mean paw withdrawal latencies
from the ipsilateral and contralateral hind paws were determined from the average of three sep-
arate trials, taken at 5 min intervals to prevent thermal sensitization and behavioral distur-
bances. Animals were habituated to the environment for 1 h before the experiment to become
quiet and to allow testing.
Thermal allodynia to cold stimulus was assessed by using the hot/cold-plate analgesia meter
(Ugo Basile), previously described by Bennett and Xie (1988) [33]. The number of elevations of
each hind paw was recorded in the mice exposed to the cold plate (4 ± 0.5°C) for 5 min.
Western Blot Analysis
CTRL animals and STZ-induced diabetes mice treated with vehicle or CoPP were killed by cer-
vical dislocation and tissues from the lumbar section of the spinal cord, dorsal root ganglia and
sciatic nerves were removed immediately after sacrifice, frozen in liquid nitrogen, and stored at
-80°C until assay. Samples from the spinal cord, dorsal root ganglia and sciatic nerves of two
and/or three animals were pooled into one experimental sample to obtain enough protein lev-
els for performing the Western blot analysis. The HO-1, CD11b/c, NOS2 and MOR protein
levels were analyzed by Western blot.
For the evaluation of HO-1, CD11b/c, NOS2, total proteins were extracted. Then tissues
were homogenized in ice-cold lysis buffer (50 mM Tris Base, 150 nM NaCl, 1% NP-40, 2 mM
EDTA, 1 mM phenylmethylsulfonyl fluoride, 0.5 Triton X-100, 0.1% sodium dodecyl sulfate, 1
mMNa3VO4, 25 mM NaF, 0.5% protease inhibitor cocktail, and 1% phosphatase inhibitor
cocktail). All reagents were purchased at Sigma (St. Louis, MO) with the exception of NP-40
from Calbiochem (Darmstadt, Germany). The crude homogenate was solubilised for 1 h at
4°C, sonicated for 10 s and centrifugated at 4°C for 15 min at 700 g. The supernatant was stored
a -80°C.
For MOR, membrane proteins were extracted. Then, tissues were homogenized in ice-cold
assay buffer (50 mM Tris-HCl, 1 mM EGTA and 5 mMMgCl2, pH 7.4) and centrifuged twice
at 48.000 g at 4°C for 20 minutes. The pellet was resuspended in assay buffer and stored a
-80°C.
Therefore, 60 μg of total or membrane proteins were mixed with 4 x laemmli loading buffer
and then loaded onto 4% stacking/10% separating sodium dodecyl sulfate polyacrylamide gels.
The proteins were electrophoretically transferred onto PVDF membrane for 120 min,
blocked with PBST + 5% nonfat dry milk, and subsequently incubated overnight at 4°C with
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polyclonal rabbit anti-HO-1 (1:300, Stressgen, Ann Arbor, MI); anti-CD11b/c (1:300, Novus
Biologicals, Littleton, CO) antibody against the type 3 complement receptor to detect activated
microglial cells; anti-NOS2 (1:200, Chemicon-Millipore) or anti-MOR (1:1000, Chemicon-
Millipore, Billerica, MA) antibodies. The proteins were detected by a horseradish peroxidase-
conjugated anti-rabbit secondary antibody (GE Healthcare, Little Chalfont, Buckinghamshire,
United Kingdom) and visualized with chemiluminescence reagents (ECL kit; GE Healthcare)
and by exposure onto hyperfilm (GE Healthcare). The intensity of blots was quantified by den-
sitometry. The membranes were stripped and reproved with a monoclonal rabbit anti-β-actin
antibody (1:10.000, Sigma) used as a loading control.
Experimental design
In a first set of experiments, we assessed the expression of neuropathic pain induced by the
intraperitoneal injection of STZ. After the habituation period, baseline responses were estab-
lished in the following sequence: von Frey filaments, plantar and cold plate tests. After baseline
measurements, diabetes was induced and animals were again tested in each paradigm at days
21 and 25 after STZ injection by using the same sequence as for baseline responses (n = 8 ani-
mals). Mice treated with an equal volume of citrate buffer (CTRL) were used as controls (n = 8
animals). Diabetic animals were randomly assigned to the treatment groups. Researchers who
performed the behavioral tests were blinded regarding treatment received by the animals.
In a second set of experiments, we evaluated the mechanical antiallodynic, thermal antihy-
peralgesic and thermal antiallodynic effects of the intraperitoneal administration of 5 and 10
mg/kg of CoPP or vehicle in diabetic mice at 21 and 25 days after STZ-injection (n = 6 animals
per group). In a third set of experiments the mechanical antiallodynic, thermal antihyperalgesic
and thermal antiallodynic effects produced by the subcutaneous administration of different
doses of morphine (0.5–10 mg/kg) or saline in diabetic mice at 21 days after STZ injection ani-
mals were also assessed (n = 6 animals per group). In a four set of experiments, we investigated
the antinociceptive effects produced by the intraperitoneal administration of 10 mg/kg of
CoPP combined with the subcutaneous administration of a low dose of morphine (0.5 mg/kg)
in STZ-injected animals (n = 6 animals per group) as well as the reversion of the antiallodynic
and antihyperalgesic effects produced by a high dose of morphine (10 mg/kg) by the adminis-
tration of 10 mg/kg of SnPP intraperitoneally administered (n = 6 animals per group). All of
these experiments were performed at 21 days after STZ-injection.
The doses of CoPP and SnPP were selected in accordance to our previous pilot studies as
well as to other works [19, 21]. The doses of morphine administered were chosen from the
dose-response curves performed in this study, as the ones that produced a minimal or a maxi-
mal antinociceptive effect in STZ-injected mice.
Finally, in another set of experiments we evaluated the effects of CoPP treatment on the
expression of HO-1 in the lumbar section of the spinal cord, dorsal root ganglia and sciatic
nerves as well as of those of CD11b/c and NOS2 in the lumbar section of the spinal cord from
STZ-injected mice by using Western blot assay. Tacking account that functional MOR are
located in plasmatic membranes, the expression of MOR were evaluated in membrane prepara-
tions from the spinal cord tissues. In these experiments mice treated with citrate buffer (CTRL)
have been used as controls (n = 4 samples per group).
Drugs
Streptozotocin were purchased from Sigma. CoPP and SnPP were acquired from Frontier sci-
entific (Livchem GmbH & Co, Frankfurt, Germany). CoPP and SnPP were dissolved in DMSO
(1% solution in saline) and morphine in saline solution (0.9% NaCl). All drugs were freshly
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prepared before use and administered in a final volume of 10 ml/kg. CoPP and SnPP were
intraperitoneally administered at 3–4 h (CoPP) and 30 min (SnPP) before behavioural testing.
Morphine was administered subcutaneously 30 min before behavioral testing. For each group
treated with a drug the respective control group received the same volume of vehicle.
Statistical Analysis
Data are expressed as mean ± SEM. The statistical analysis was performed by using the SPSS
(version 17 for Windows, IBM España, Madrid, Spain). All comparisons were run as two-tailed
testing. The comparison of the glucose levels in STZ-injected mice versus citrate buffer treated
mice was evaluated by using an unpaired Student t test. The comparison of the mechanical
allodynia, thermal hyperalgesia, and thermal allodynia induced by administration of STZ plus
vehicle or CoPP at different doses and time points was evaluated by using a two way ANOVA
repeated measures followed by the corresponding one way ANOVA and the Student Newman
Keuls test. The effects produced by the administration of several doses of morphine or saline
were evaluated by using a one way ANOVA followed by the Student Newman Keuls test.
For each behavioral test, the comparison of the effects produced by the administration of
CoPP or SnPP on the antinociceptive actions of morphine was also evaluated by using a one
way ANOVA followed by the Student Newman Keuls test.
In these experiments, mechanical allodynia is expressed as the von Frey filaments strength
(g), thermal hyperalgesia as the withdrawal latency (s) and thermal allodynia as the number of
hind paws lifts.
Changes on the expression of HO-1, CD11b/c, NOS2 andMOR from CTRL and STZ-injected
mice treated with vehicle or CoPP were analyzed by using a one way ANOVA followed by the
Student Newman Keuls test. A value of p<0.05 was considered as a significant.
Results
Induction of diabetic neuropathy
In accordance to other reports, the administration of STZ produced weight loss (26.1 ± 0.6 g in
CTRL mice versus 23.6 ± 0.5 g in STZ-injected animals; p< 0.01; unpaired Student t test; n = 8
animals per group) and a significant increase in plasma glucose levels (23.2 ± 0.4 mmol/l in
STZ-injected animals versus 7.9 ± 0.2 mmol/l in CTRL mice; p<0.001; unpaired Student t test;
n = 8 animals per group).
Effect of CoPP treatment on the development of diabetic neuropathy
Animals were intraperitoneally daily treated with CoPP at 5 and 10 mg/kg or vehicle for a
period of 5 days. On days 1 and 5 of treatment, the mechanical allodynia, thermal hyperalgesia
and thermal allodynia were assessed. For all tests the two-way ANOVA repeated measures
revealed a significant effect of the treatment (p<0.001) and time (p<0.001), and a significant
interaction between them (p<0.001). That is, the significant decrease of the threshold for
evoking hind paw withdrawal to a mechanical stimulus (Fig 1, panel A) and to a thermal
stimulus (Fig 1, panel B) as well as the increased number of paw lifts during cold thermal stim-
ulation (Fig 1, panel C) observed in STZ-vehicle treated mice were significantly attenuated or
completely blocked in animals treated with CoPP at 5 and 10 mg/kg during 5 consecutive days,
respectively. Moreover, while the mechanical and thermal allodynia as well as hyperalgesia
induced by the administration of STZ were attenuated in animals treated with CoPP at 5 or 10
mg/kg during 1 day (p<0.001; one way ANOVA vs. CTRL animals), at 5 days of treatment,
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Fig 1. The antinociceptive effects produced by the intraperitoneal administration of CoPP at 5 and 10
mg/kg in STZ injectedmice. The development of mechanical allodynia (A), thermal hyperalgesia (B) and
thermal allodynia (C) in the hind paws of control and diabetic mice intraperitoneally treated with vehicle or
CoPP at 5 and 10 mg/kg from day 21 to day 25 after STZ injection is shown. Data of tests are shown at day 0
(before diabetes induction) and at days 21 and 25 after STZ injection (one and five days after initiation of
CoPP administration, respectively). Data are expressed as von Frey filaments strength (g) for mechanical
Heme Oxygenase 1 Induction Inhibits Neuropathy
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these nociceptive effects were only completely blocked in animals treated with 10 mg/kg of
CoPP.
In CTRL mice, CoPP treatment did not produce any effect compared to mice treated with
vehicle (data not shown).
Effects of the subcutaneous administration of morphine on the mechanical allodynia, ther-
mal hyperalgesia and thermal allodynia induced by STZ injection in mice
The subcutaneous administration of morphine (0.5–10 mg/kg) dose-dependently inhibited
the mechanical allodynia (Fig 2A), thermal hyperalgesia (Fig 2B) and thermal allodynia (Fig
2C) induced by STZ injection. Indeed, the mechanical antiallodynic and thermal antihyperal-
gesic effects produced by the administration of morphine at 1, 3 and 10 mg/kg were higher
than those produced by saline administration (p<0.001, one way ANOVA followed by the Stu-
dent Newman Keuls test). In addition, the thermal antiallodynic effects produced by 3 and 10
mg/kg of morphine were also significantly different to those produced by saline (p<0.016, one
way ANOVA followed by the Student Newman Keuls test).
Effects of CoPP treatment on the antiallodynic and antihyperalgesic
responses to morphine in STZ-injected mice
The effects of the intraperitoneal administration of 10 mg/kg of CoPP or vehicle (DMSO 1%)
on the mechanical antiallodynic (Fig 3A), thermal antihyperalgesic (Fig 3B) and thermal
antiallodynic (Fig 3C) effects produced by the subcutaneous administration of a low dose of
morphine (0.5 mg/kg) or saline in STZ-injected mice were investigated. Our results showed
that treatment with CoPP combined with the subcutaneous administration of a low dose of
morphine significantly enhanced the mechanical antiallodynic (Fig 3A), thermal antihyperal-
gesic (Fig 3B) and thermal antiallodynic (Fig 3C) effects produced by morphine, CoPP or
vehicle administered alone (p<0.001; one-way ANOVA followed by the Student Newman
Keuls test).
Reversal of the antinociceptive responses produced by morphine in
STZ-injected mice with the administration of the HO-1 inhibitor, SnPP
The effects of the intraperitoneal administration of 10 mg/kg of SnPP or vehicle (DMSO 1%)
on the inhibition of the mechanical allodynia, thermal hyperalgesia and thermal allodynia pro-
duced by the subcutaneous administration of a high dose of morphine (10 mg/kg) in STZ-
injected mice are shown in Table 1. Our results showed that the coadministration of SnPP
with a high dose of morphine significantly reversed the mechanical antiallodynic, thermal
antihyperalgesic and thermal antiallodynic effects produced by this drug administered alone
(p<0.001, one-way ANOVA followed by the Student Newman Keuls test). Moreover, the intra-
peritoneal administration of SnPP plus saline did not produce any mechanical antiallodynic,
thermal antihyperalgesic and thermal antiallodynic effect as compared with vehicle plus saline
treated mice.
allodynia, withdrawal latency (s) for thermal hyperalgesia and paw lifts (number) for thermal allodynia. For
each day, * indicates significant differences vs. CTRL mice (p< 0.05, one-way ANOVA followed by the
Student Newman Keuls test) and + indicates significant differences vs. STZ mice treated with CoPP at 10 mg/
kg (p< 0.05, one-way ANOVA followed by the Student Newman Keuls test). The results are shown as the
mean values ± SEM; n = 6–8 animals per group.
doi:10.1371/journal.pone.0146427.g001
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Fig 2. Effects of the subcutaneous administration of morphine on the mechanical allodynia, thermal
hyperalgesia and thermal allodynia induced by the administration of STZ.Mechanical antiallodynic (A),
thermal antihyperalgesic (B) and thermal antiallodynic (C) effects produced by the subcutaneous
administration of different doses of morphine in STZ-injected mice. Data are expressed as von Frey filaments
strength (g) for mechanical allodynia, withdrawal latency (s) for thermal hyperalgesia and paw lifts (number)
for thermal allodynia. For each test, * denotes significant differences versus saline treated mice (0 mg/kg) (p<
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Effect of CoPP treatment on HO-1, CD11b/c, NOS2 and MOR protein
expression
The protein levels of HO-1in the spinal cord, dorsal root ganglia and sciatic nerve from STZ-
injected mice treated with vehicle or CoPP as well as from CTRL mice treated with vehicle are
shown in Fig 4. Our results demonstrated that while the spinal cord (Fig 4A) and dorsal
root ganglia (Fig 4B) protein levels of HO-1 were not altered in diabetic mice, a reduced expres-
sion was observed in sciatic nerves of diabetic mice as compared to CTRL animals (Fig 4C;
p<0.001; one-way ANOVA followed by the Student Newman Keuls test). Nevertheless, a sig-
nificant increase in HO-1 protein levels was observed in the spinal cord, dorsal root ganglia
and sciatic nerves of diabetic mice treated with CoPP (p<0.025; one-way ANOVA, followed by
the Student Newman Keuls test, versus CTRL and STZ vehicle treated mice).
We also investigated whether the significant increased expression of CD11b/c and NOS2 in
the spinal cord from STZ vehicle treated animals (p<0.010; one-way ANOVA versus CTRL
vehicle treated mice) could be altered by CoPP treatment (Fig 5A and 5B). Our data revealed
that CoPP treatment blocked the increased expression of CD11b/c and NOS2 induced by dia-
betes (p<0.017; one-way ANOVA versus STZ vehicle treated mice).
Our results also indicated that membrane MOR protein levels were marginally reduced in
the spinal cord of diabetic mice and significantly increased in CoPP treated animals (p<0.001;
one-way ANOVA versus CTRL and STZ vehicle treated mice; Fig 5C).
Discussion
In this study, we demonstrated that the intraperitoneal administration of CoPP attenuated
painful diabetic neuropathy and increased the antinociceptive effects of morphine. Further-
more, CoPP treatment enhanced the HO-1 and MOR levels and decreased the activation of
microglia and the up-regulation of NOS2 in the spinal cord from diabetic mice.
Our results showed that the intraperitoneal injection of STZ in mice exhibited hyperglyce-
mia, weight loss as well as to mechanical and thermal allodynia, and thermal hyperalgesia at 21
days after diabetes induction. Although this model is not probably the best to make its transla-
tion to human diabetic polyneuropathy due to the short duration of the experimental process
[30] the presence of mechanical and thermal hypersensivity, as previously observed in other
short-term diabetes models [34], supported its use for studying the antinociceptive actions pro-
duced by the administration of CoPP alone and combined with morphine during painful dia-
betic neuropathy.
CoPP is a well-established HO-1 inducer compound with recognized antinociceptive and
antiinflammatory properties in several experimental models of inflammatory and neuropathic
pain [14, 18–20, 35]. Our results showed for the first time that the repeated administration of
CoPP completely abolished the mechanical and thermal allodynia as well as the thermal hyper-
algesia induced by the injection of STZ. Consistently, the protein levels of HO-1 in the spinal
cord, dorsal root ganglia and sciatic nerves from diabetic mice treated with CoPP were signifi-
cantly increased. In accordance to these results, an increased expression of HO-1 in diabetic
animals treated with several HO-1 inducer compounds have been also reported in different tis-
sues such as, spinal cord, pancreas, kidney [36–38]. In all of these experiments an improvement
of the principal symptoms of diabetes have been also revealed in CoPP treated animals, indicat-
ing that the increased expression of HO-1 induced by this treatment is the principal responsible
0.05; one-way ANOVA followed by the Student Newman Keuls test). The results are shown as the mean
values ± SEM; n = 6 animals for dose.
doi:10.1371/journal.pone.0146427.g002
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Fig 3. Effects of CoPP treatment on the antiallodynic and antihyperalgesic responses to morphine.
Mechanical antiallodynic (A), thermal antihyperalgesic (B), and thermal antiallodynic (C) effects of the
subcutaneous administration of 0.5 mg/kg of morphine or saline in STZ-injected mice pretreated with vehicle
(DMSO 1%) or 10 mg/kg of CoPP. The effects of the intraperitoneal administration of CoPP alone are also
shown. Data are expressed as von Frey filaments strength (g) for mechanical allodynia, withdrawal latency
(s) for thermal hyperalgesia and paw lifts (number) for thermal allodynia. For each behavioral test, * denotes
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for their neuroprotective effects in diabetic animals. We have previously demonstrated that the
repeated intraperitoneal injection of CoPP also inhibited the sciatic nerve injury-induced neu-
ropathic pain and inflammatory pain by increasing the expression of HO-1 [14, 19]. The pres-
ent data indicate that HO-1 also plays an important role in mediating the antinociceptive
effects of CoPP on neuropathic pain induced by diabetes mellitus.
Our results also showed that while the spinal cord and dorsal root ganglia protein levels of
HO-1 were not altered by diabetes a significant reduction in its expression was observed in
sciatic nerves of diabetic mice as compared to controls. These results are in contrast to the
enhanced expression of HO-1 observed in the spinal cord of diabetic animals [36] but agree
with the down-regulated protein levels of this enzyme shown in sciatic nerves of diabetic ani-
mals [39]. The possible discrepancies in the spinal cord levels of HO-1in diabetic mice could be
probably related to the different evaluation times after diabetes induction (3 vs. 6 weeks) as
well as the different molecular techniques used to evaluate their expression (western blot vs.
immunohistochemistry). Nevertheless, the reduced HO-1 levels in sciatic nerve of diabetic ani-
mals is among the consequence of hyperglycemia that contribute to prevailing oxidative stress
condition in peripheral nerves [39]. CoPP treatment enhanced the levels of this enzyme in sci-
atic nerves and spinal cord thus exerting a protective effect in diabetic neuropathy.
Several authors have demonstrated the important role played by spinal microglial cells in
the development of diabetic neuropathy [22]. That is, activated microglia promotes the consoli-
dation and progression of painful diabetic neuropathy by regulating the synthesis of several
inflammatory mediators, such as nitric oxide. In this study we have also demonstrated that
CoPP treatment inhibited microglial activation in the spinal cord from diabetic mice. There-
fore and taking account the reduced behavioral symptoms of neuropathic pain observed in
diabetic mice treated with selective inhibitors of microglial activation [11] and the reduced
expression of CD11b/c (a marker of microglial activation) in the spinal cord of diabetic mice
treated with CoPP, that we hypothesized that the antinociceptive effects of CoPP in diabetic
mice might, at least in part, be mediated through the inhibition of the spinal microglial
activation.
It is also well known that under neuropathic pain conditions, HO-1 may exert its antinoci-
ceptive effects via modulation the expression of NOS2 [14, 21]. Therefore, the reduced protein
significant differences versus control group treated with vehicle plus saline (p< 0.05, one-way ANOVA
followed by Student Newman Keuls test), + denotes significant differences versus group treated with vehicle
plus morphine (p< 0.05, one-way ANOVA followed by the Student Newman Keuls test) and # denotes
significant differences versus group treated with CoPP plus saline (p< 0.05; one-way ANOVA followed by the
Student Newman Keuls test).
doi:10.1371/journal.pone.0146427.g003
Table 1. Mechanical response (von Frey filaments strength, g), thermal heat response (withdrawal latency, s) and thermal cold response (paw
lifts, number) on the hind paws of STZ injectedmice treated with vehicle-saline, vehicle-morphine, SnPP-saline or SnPP-morphine.
Treatment Mechanical response von Frey ﬁlaments
strength (g)
Thermal heat response withdrawal
latency (s)
Thermal cold response paw lifts
(number)
vehicle-saline 1.4 ± 0.1 5.1 ± 0.3 2.8 ± 0.2
vehicle-
morphine
2.4 ± 0.1* 9.4 ± 0.3* 0.6 ± 0.4*
SnPP-saline 1.2 ± 0.1 5.8 ± 0.8 2.6 ± 0.9
SnPP-morphine 1.5 ± 0.1 5.7 ± 1.0 3.0 ± 0.7
Results are shown as mean values ± SEM; n = 6 animals per experimental group. For each test,
* p<0.001 denotes signiﬁcant differences vs the other experimental groups (one way ANOVA followed the Student Newman Keuls test).
doi:10.1371/journal.pone.0146427.t001
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levels of NOS2 observed in the spinal cord from diabetic mice treated with CoPP suggests that
the alleviation of diabetic neuropathy produced by this HO-1 inducer compound might be also
due by blocking the spinal synthesis of nitric oxide produced by NOS2. We do not exclude the
possibility that CoPP might also exert its anticonception effects via modulation of cGMP sig-
naling pathway in spinal neurons [40] as well as by reducing the up-regulated expression of
COX-2 as shown in other diabetic models [39, 41]. Nevertheless, because oxidative stress and
inflammation play a pivotal role in the development and progression of diabetic complications,
such us painful diabetic neuropathy [39], this study demonstrated that the activation of HO-1
may provide beneficial effects in neuropathy, as demonstrated by the inhibition of activated
microglia and the synthesis of nitric oxide induced by diabetes.
In the present study, we also demonstrated for the first time that the antiallodynic and anti-
hyperalgesic effects of subcutaneous administration of morphine in diabetic mice were signifi-
cantly enhanced by CoPP treatment. This finding represents an interesting improvement in
the therapy of painful diabetic neuropathy taking account the loss antinociceptive efficacy of
morphine in these experimental conditions. Moreover, the effective antinociceptive effects pro-
duced by the combination of a small dose of morphine with CoPP might avoided the possible
side effects produced by this opioid when was repetitively administered a high doses. In addi-
tion, the fact that the antinociceptive effects of morphine were completely reversed by the
administration of an HO-1 inhibitor (SnPP) revealed the involvement of HO-1 in the inhibi-
tory effects produced by morphine during painful diabetic neuropathy.
The possible mechanisms implicated in the increased antinociceptive effects of morphine
produced by CoPP under painful diabetic neuropathy state are not elucidated. Our data
Fig 4. Effect of CoPP treatment on HO-1 protein expression in the spinal cord, dorsal root ganglia and sciatic nerve from STZ-injected mice. The
protein expression of HO-1 in the spinal cord (A), dorsal root ganglia (B) and sciatic nerve (C) from STZ-injected mice treated with vehicle or CoPP is
represented. The expression of HO-1 in the spinal cord, dorsal root ganglia and sciatic nerve from CTRLmice treated with vehicle has been also represented
as controls. For each tissue, * indicates significant differences when compared to CTRL mice (p< 0.05, one-way ANOVA followed by Student Newman Keuls
test) and + when compared to STZ vehicle treated mice (p< 0.05, one-way ANOVA followed by Student Newman Keuls test). Representative examples of
western blots for HO-1 (32 kDa) in which β-actin (42 kDa) was used as a loading control, are also shown. Data are expressed as the relative
expression ± SEM; n = 4 samples per group.
doi:10.1371/journal.pone.0146427.g004
Heme Oxygenase 1 Induction Inhibits Neuropathy
PLOS ONE | DOI:10.1371/journal.pone.0146427 January 5, 2016 13 / 17
demonstrated that while STZ-induced diabetes slightly reduced the membrane MOR levels in
the spinal cord, and an enhanced expression of these receptors was observed in CoPP treated
mice. That is, the expression of MOR in CoPP treated animals was higher than those obtained
in controls and STZ-injected mice treated with vehicle, indicating that CoPP treatment not
only avoided the diminished expression of MOR induced by diabetes but rather increased their
protein in diabetic animals. Thus explaining the increased effectiveness of morphine in CoPP
diabetic treated mice. These data are consistent with previous findings showing that the activa-
tion of HO-1 increased morphine effectiveness in animals with neuropathic pain induced by
the chronic constriction of the sciatic nerve in mice by enhancing MOR expression [21]. Nev-
ertheless, in addition to the enhanced expression of MOR produced by CoPP treatment,
changes in the functional coupling of MOR to G proteins, in the density of distinct G protein
subunits, etc. induced by the activation of HO-1 might not be excluded.
The non-significant changes in the protein levels of MOR in the spinal cord from diabetic
mice treated with vehicle are in accordance to the unchanged expression of MOR observed in
the majority of investigations performed after 3–4 weeks of STZ-induced diabetes [5, 42] but in
contrast to the down-regulated expression of these receptors demonstrated by Shaqura et al.,
(2013) [43] in the spinal cord from diabetic rats at 12 weeks after STZ injection. These discrep-
ancies are probably related to the different period of time allowed after STZ-induced diabetes,
that is the early (3–4 weeks) and at more advanced stage (12 weeks).
It is also well known that treatment with selective inhibitors of microglial activation besides
to reduce the behavioral symptoms of neuropathic pain in diabetic mice, also enhanced the
antinociceptive effects of morphine systemically administered [11]. Therefore, the fact that
Fig 5. Effect of CoPP treatment on CD11b/c, NOS2 andMOR protein expression in the spinal cord from STZ-injected mice. The protein expression of
CD11b/c (A), NOS2 (B) and MOR (C) in the spinal cord from STZ-injected mice treated with vehicle or CoPP is represented. The expression of CD11b/c,
NOS2 and MOR from CTRLmice treated with vehicle has been also represented as controls. For each protein, * indicates significant differences when
compared to CTRL animals (p< 0.05, one-way ANOVA followed by Student Newman Keuls test), + indicates significant differences when compared to STZ
vehicle treated animals (p< 0.05, one-way ANOVA followed by Student Newman Keuls test) and # indicates significant differences when compared to
STZ-CoPP treated animals (p< 0.05, one-way ANOVA followed by Student Newman Keuls test). Representative examples of western blots for CD11b/c (160
kDa), NOS2 (130 kDa) and MOR (50 kDa) proteins, in which β-actin (42 kDa) was used as a loading control, are also shown. Data are expressed as the
relative expression ± SEM; n = 4 samples per group.
doi:10.1371/journal.pone.0146427.g005
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CoPP treatment avoided the activation of microglia in diabetic mice indicated that the induc-
tion of HO-1 might also increase the antinociceptive effects of morphine via inhibiting micro-
glia activation.
In conclusion, our results demonstrated that the induction of HO-1 might alleviate diabetic
neuropathy and enhanced the antinociceptive effects of morphine via inhibition of microglia
activation and NOS2 overexpression as well as by regulating MOR spinal cord expression.
These data provide promising therapeutic approaches for the treatment of STZ-induced pain-
ful diabetic neuropathy.
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